We can't find the internet
Attempting to reconnect
13952.1 PFLS-LS
13952.1 PFLS-LS
Zusammenfassung
MVX-ONCO-1: Encapsulation cell therapy for cancer immunotherapy: First in Man Clinical Study
Weitere Texte
Abstract
MaxiVAX SA, in collaboration with HUG and EPFL, has developed a novel, patient-specific, cell-based|immunotherapy, combining irradiated cancer cells and biocompatible capsules containing a cell line|producing a strong immune-stimulator. In May 2011, MaxiVAX¿ innovative immunization approach was|classified as an Advanced Therapeutic Product by the European Medicines Agency. The project is now|under regulatory review by SwissMedic and it expected that a first-in-man study in 15 patients can begin in|Q1-2012 with the infrastructure fully in place at the Cell Therapy Center at the HUG. This work provides an|essential milestone for the further validation development of effective novel anti-cancer therapies.
Beteiligte
Nicolas Mach
Kontaktperson
nicolas.mach@hcuge.ch
HUG Hôpitaux Universitaires de Genève CHE-113.514.289 Nicolas Mach Rue Gabrielle-Perret-Gentil 4 1205 Genève GE CH
Clarence Peter
Wirtschaftspartner
cpeter@pplex.ch
MaxiVAX SA Clarence Peter Rue François Bellot 6 1206 Geneva GE CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2013-01-31
- Enddatum
- 2015-07-31
- Bewilligte Gesamtkosten
- CHF 150000.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Industrielle Produktivität und Technologie
Forschungsdisziplinen
- T115 Medical technology 100.0%